Systemic Lupus Erythematosus

Comparable Risk for Atherosclerosis in Antiphospholipid Syndrome and Diabetes

Comparable Risk for Atherosclerosis in Antiphospholipid Syndrome and Diabetes

By

Patients with primary antiphospholipid syndrome and systemic lupus erythematosus-associated antiphospholipid syndrome have an almost 2.5-fold risk for development of atherosclerotic plaques in carotid and femoral arteries compared with healthy control patients.

Predictors of Incident Proteinuria in Systemic Lupus Erythematosus

Predictors of Incident Proteinuria in Systemic Lupus Erythematosus

By

Older patients with SLE are at a low risk for the development of proteinuria.

Failure to Achieve Low Disease Activity Linked to Early Damage Accrual in SLE

Failure to Achieve Low Disease Activity Linked to Early Damage Accrual in SLE

By

Lupus low disease activity state has been shown to be achievable and negatively associated with early damage accrual.

Neonatal Lupus: Clinical Manifestations and Treatment Options

Neonatal Lupus: Clinical Manifestations and Treatment Options

By

Neonatal systemic lupus erythematosus syndrome develops as a result of passively acquired autoimmunity, when autoantibodies produced by the mother cross the placenta, affecting the developing fetus.

Consistent Antimalarial Intake in First 5 Years of SLE Linked to Improved Prognosis

Consistent Antimalarial Intake in First 5 Years of SLE Linked to Improved Prognosis

By

Investigators evaluated long-term outcomes with antimalarial use and organ damage, flares, disease activity, glucocorticoid use, and antimalarial associated retinopathy.

Identifying SLE-Related Health Demands Using Data Mining, Big Data

Identifying SLE-Related Health Demands Using Data Mining, Big Data

By

"Infodemiology" and "infoveillance" are terms used to describe an emerging approach to public health research, based on Google Trends big data monitoring and data mining.

The Future of Precision Medical Care for Rheumatic Disease

The Future of Precision Medical Care for Rheumatic Disease

Virginia Pascual, MD, discusses precision medicine for rheumatic diseases.

Evidence-Based Recommendations for the Diagnosis, Treatment of Childhood-Onset Lupus Nephritis

Evidence-Based Recommendations for the Diagnosis, Treatment of Childhood-Onset Lupus Nephritis

By

The SHARE initiative has formulated evidence-based recommendations for the diagnosis and treatment of lupus nephritis childhood-onset lupus nephritis.

Maternal Systemic Lupus Erythematosus May Increase Risk for Childhood Asthma

Maternal Systemic Lupus Erythematosus May Increase Risk for Childhood Asthma

By

Maternal systemic lupus erythematosus during pregnancy is associated with increased risk for asthma in children.

Switching Antimalarial Agent in Patients With Cutaneous Lupus Erythematosus

Switching Antimalarial Agent in Patients With Cutaneous Lupus Erythematosus

By

Switching from 1 antimalarial agent to a second may be beneficial in patients with cutaneous lupus erythematosus.

Systemic Lupus Erythematosus Mortality Rates Decreased in the United States from 1968 to 2013

Systemic Lupus Erythematosus Mortality Rates Decreased in the United States from 1968 to 2013

By

Rates of SLE mortality have declined, but remain high relative to non-SLE mortality.

Atacicept Effective for Systemic Lupus Erythematosus Activity, Severity

Atacicept Effective for Systemic Lupus Erythematosus Activity, Severity

By

Atacicept may be safe and effective for lowering disease activity and severity in patients with active systemic lupus erythematosus.

Active Nephritis in Active SLE: Identification of a New Biomarker

Active Nephritis in Active SLE: Identification of a New Biomarker

By

Anti-ficolin-2 autoantibodies may represent a biomarker for renal manifestations in patients with active systemic lupus erythematosus.

Association Between SLE Disease Activity and Omega Fatty Acids, Vitamin D

Association Between SLE Disease Activity and Omega Fatty Acids, Vitamin D

Low vitamin D is linked with later total organ and renal damage in patients with SLE.

EULAR/ACR Systemic Lupus Erythematosus Classification Criteria Update

EULAR/ACR Systemic Lupus Erythematosus Classification Criteria Update

By

EULAR and ACR jointly funded and collaborated on creating a set of criteria that can be used to more accurately identify patients with SLE for inclusion in clinical trials.

Obesity, Disease Activity Paradox Found in Systemic Lupus Erythematosus

Obesity, Disease Activity Paradox Found in Systemic Lupus Erythematosus

By

Researchers studied how BMI changes would affect disease activity in systemic lupus erythematosus

Pregnancy Outcomes in SLE vs Other Connective Tissue, Inflammatory Rheumatic Conditions

Pregnancy Outcomes in SLE vs Other Connective Tissue, Inflammatory Rheumatic Conditions

By

Real-world data indicate that although most patients with systemic lupus erythematosus or connective tissue diseases have successful pregnancies, more adverse pregnancy outcomes occur.

Obesity Leads to Poor Outcomes for Patients with Systemic Lupus Erythematosus

Obesity Leads to Poor Outcomes for Patients with Systemic Lupus Erythematosus

By

The impact of excess adiposity in SLE has not been established, despite obesity being a common comorbidity in SLE.

Childhood-Onset SLE Predicts Steroid Damage Over Time

Childhood-Onset SLE Predicts Steroid Damage Over Time

By

Little is known about differences in long-term steroid toxicity between adults with cSLE and aSLE.

Systemic Lupus Erythematous Responder Index: Primary Drivers

Systemic Lupus Erythematous Responder Index: Primary Drivers

By

The efficacy variables with the greatest effect on systemic lupus erythematous (SLE) Responder Index responder status in clinical trials include SLE Disease Activity Index improvement, concomitant medication adherence, and trial completion.

Unmet Needs in the Pathogenesis, Treatment of Systemic Lupus Erythematosus

Unmet Needs in the Pathogenesis, Treatment of Systemic Lupus Erythematosus

By

Improved survival has ushered in new challenges that inadvertently increase the risk for death in patients with SLE.

Anti-Ro/SSA-Positive Pregnancies and Fetal Cardiac Conduction Disturbances

Anti-Ro/SSA-Positive Pregnancies and Fetal Cardiac Conduction Disturbances

By

The recurrence of fetal cardiac conduction disturbances in the fetuses of women expressing anti-Ro/SSA antibodies may be influenced by the season of the year and maternal age.

Cardiovascular Disease Risk in Patients With Systemic Lupus Erythematosus

Cardiovascular Disease Risk in Patients With Systemic Lupus Erythematosus

By

Improved treatment in SLE with increased life expectancy has been accompanied by an elevated risk for developing cardiovascular diseases.

Impact of Remission, Low Disease Activity on Outcomes in Lupus

Impact of Remission, Low Disease Activity on Outcomes in Lupus

By

While a treat to target strategy has been proposed for managing SLE, the impact of possible disease outcomes has not been fully evaluated.

Systemic Lupus Erythematosus-Associated Cognitive Impairment May Be Identified With New Screening Tool

Systemic Lupus Erythematosus-Associated Cognitive Impairment May Be Identified With New Screening Tool

By

The high prevalence of cognitive impairment in patients with SLE creates a need for a reliable and cost-effective screening tool.

Hydroxychloroquine Effects on Cholesterol Levels in Systemic Lupus Erythematosus

Hydroxychloroquine Effects on Cholesterol Levels in Systemic Lupus Erythematosus

By

Research revealed that hydroxychloroquine is associated with reduced LDL-C and total cholesterol levels in patients with lupus.

Advancing Understanding of Shrinking Lung Syndrome in SLE

Advancing Understanding of Shrinking Lung Syndrome in SLE

By

The diagnosis and management of shrinking lung syndrome, a rare complication of systemic lupus erythematosus, is discussed in a comprehensive review.

No Increased Risk of SLE Found With Current Statin Use

No Increased Risk of SLE Found With Current Statin Use

By

The risk of developing SLE in current statin users aged ≥40 years was no different than that in nonusers.

Venetoclax Safe, Effective in Women With Systemic Lupus Erythematosus

Venetoclax Safe, Effective in Women With Systemic Lupus Erythematosus

By

Use of the anti-apoptotic protein B-cell lymphoma 2 inhibitor venetoclax reduced total lymphocyte and disease-relevant B cells in women with SLE.

Chronic Inflammatory Disorders May Increase Cardiometabolic, Mortality Risks

Chronic Inflammatory Disorders May Increase Cardiometabolic, Mortality Risks

By

The degree of risk for cardiometabolic events and all-cause mortality appeared to increase in participants who took nonsteroidal anti-inflammatory drugs or corticosteroid drugs.

Sign Up for Free e-newsletters